Sanofi to buy Genzyme
In addition to the cash payment, each Genzyme shareholder will receive one contingent value right (CVR) for each share they own, entitling the holder to receive additional cash
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
PRIMACYT Cell Culture Technology GmbH provides in-vitro technology services to the pharmaceutical and biotech industry. It currently offers hepatocyte cells to the drug discovery research community throughout Europe.